Pediatric Palliative Care
New Drug Targets Root Cause of IgAN by Blocking Immune Cell Signals
AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
When something is rare, it’s often overlooked. Sharing and learning about conditions like Pompe disease helps bring visibility, understanding, and support where it’s needed most! #PompeDisease #RareDisease #RareDiseaseOfTheWeek #ShareYourStory #PatientWorthy
Preparing for your first specialist visit? Swipe for a full preparation guide and practical steps to help maximize your appointment. #SpecialistVisit #HealthcareNavigation #patientadvocacy #PatientWorthy
Share your patient story with us here: bit.ly/4dV7gru
Latify, a new drug developed by AstraZeneca, has missed the mark in a trial aimed at treating NSCLC. Read more here:
patientworthy.com/2026/01/20/astrazenecas-latify-trial-misses-primary-endpoint-in-previously-trea...
